Prognostic values of high sensitivity cardiac troponin T and I for long-term mortality in hemodialysis patients

Kajohnsak Noppakun1,4, Kannika Ratnachina2, Nichanan Osataphan2, Arintaya Phrommintikul2,3 & Wanwarang Wongcharoen2*

Previous studies using contemporary cardiac troponin (cTn) assays have shown conflicting results in predictability of mortality and major adverse cardiovascular events (MACEs) in hemodialysis patients. We aimed to evaluate the prognostic values of high-sensitivity cTnT (hs-cTnT) and hs-cTnI for long-term mortality and MACEs in asymptomatic chronic hemodialysis patients. 198 asymptomatic patients undergoing regular hemodialysis (age 62.4 ± 14.8 years) were enrolled. Pre-dialysis hs-cTnT and hs-cTnI levels were measured. The study outcomes were long-term all-cause mortality and MACEs. Median values of hs-cTnT and hs-cTnI were 61.1 ng/L (IQR 36.6–102.0) and 18.4 ng/L (IQR 9.5–36.6), respectively. During a median follow-up of 13.5 months, 30 (15.1%) patients developed MACEs, and 20 (10.1%) patients died. The patients in highest quartile of hs-cTnT level (≥ 102 ng/L) had increased risk of long-term mortality (HR 3.34; 95%CI 1.39–8.04, P = 0.005). However, hs-cTnI levels above highest quartile (≥ 36 ng/L) was not significantly associated with increased risk of all-cause mortality. Nevertheless, elevated level of hs-cTnT and hs-cTnI was associated with increased risk of MACEs. We demonstrated that higher level of hs-cTnT, but not hs-cTnI, was associated with increased risk of long-term mortality. Nevertheless, higher level of hs-cTnT and hs-cTnI both were associated with greater risk of long-term MACEs.

It is well-established that the patients with chronic hemodialysis had a markedly higher rate of cardiovascular death and all-cause death than the general population. Early recognition of patients undergoing hemodialysis with heightened mortality risk is essential for the early intervention and attentive therapy. Multiple biomarkers have been explored to be used as a predictor of long-term adverse outcome in this population. Several investigators have shown that asymptomatic patients with end-stage renal disease (ESRD) have chronically elevated levels of cardiac troponin (cTn)2-4. Recent studies have demonstrated that nearly all of patients with regular dialysis had a raised level of high-sensitivity cTnT (hs-cTnT), while around one-third of patients had an increased level of high sensitivity cTnI (hs-cTnI)6-9. The dissimilar findings between cTnT and cTnI may be attributable to the distinctions in cellular distribution, biochemical, genetic, and kinetic features10,11. With this regard, it has been suggested that hs-cTnT may be more favorable in the diagnostic use of patients with suspected acute coronary syndrome6. However, in terms of prognostic values between cTnT and cTnI in patients with ESRD, the data are still conflicting3,12,13. In addition, conventional cardiac troponin assay used in those studies may have drawback of limited sensitivity and specificity as compared to high-sensitivity assay. Based on the revised definition of myocardial infarction with strict recommendations on test precision, the high sensitivity assay of cardiac troponin T and I has gained popularity in its use. As a result, we aim to evaluate and compare the prognostic value of the hs-cTnT and hs-cTnI assay for long-term mortality and major adverse cardiovascular events (MACEs) in asymptomatic patients receiving regular hemodialysis.

1Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 2Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 3Center for Medical Excellence, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. 4Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand. *email: bwanwarang@yahoo.com
Methods

Study population. In this prospective observational cohort study, ESRD patients, aged more than 18 years, who had undergone regular hemodialysis for more than 3 months at the hemodialysis unit at Chiang Mai University hospital were enrolled. All of the participants who had an acute myocardial infarction, heart failure, or pulmonary embolism within the past 6 months; recent major or traumatic surgery within the last 4 weeks; and recent coronary and/or valvular surgery within the last 6 months were excluded from this study. A total of 200 patients with chronic hemodialysis were screened for eligibility. Two patients were excluded due to the occurrence of acute coronary syndrome in one patient and heart failure requiring hospitalization in one patient within the past 6 months. As a result, there were 198 asymptomatic patients with chronic hemodialysis enrolled in this study during a period of September 2020 to January 2021. Patients who underwent a kidney transplant or who were lost to follow-up were censored on the day of the transplant as well as the day of their final visit. This study was approved by the institutional research board of Faculty of Medicine, Chiang Mai University (Approval No. 182/2564). Informed consent and all procedure followed the Declaration of Helsinki and ethical standards of the responsible committee on human experimentation.

Clinical data and laboratory measurements. Clinical data were acquired at the time of study entry, including age, gender, cardiovascular risk factors, medication, comorbidity, blood chemistry, and hemodialysis data (dialysis duration, frequency, and access). The pre-dialysis hs-cTnT and hs-cTnI levels were measured in all subjects (single measurement). Several studies have revealed that cardiovascular events are more frequently after a long interdialytic interval than after a short interdialytic interval during hemodialysis sessions. Therefore, we chose to obtain the blood sample of pre-dialysis hs-cTnT and hs-cTnI levels during the long dialytic period. The hs-cTnT was analyzed by electroimmunooassay using Cobas e801 (Roche Diagnostics) and hs-cTnI with the ARCHITECT i2000SR Diagnostic System (Abbott). The limit of detection was 3 ng/L for hs-cTnT and 3.2 ng/L for hs-cTnI, and the coefficients of variation below 10% were 13 ng/L and 4.7 ng/L for hs-cTnT and hs-cTnI. The cutoff at the 99th percentile was 14 ng/L for hs-cTnT and 26.2 ng/L for hs-cTnI.

The study endpoints. All participants were followed for the first occurrence of all-cause mortality and MACEs until September 2021. The primary endpoint was the prognostic values of hs-cTnT and hs-cTnI on all-cause mortality, with the secondary endpoint being the prognosis for MACEs. MACEs were defined as a composite outcome of nonfatal myocardial infarction, heart failure hospitalization, and death from any cause.

Statistical analysis. Continuous variables were expressed as means and standard deviations when normally distributed, or medians and interquartile ranges when not normally distributed. The comparison across the different groups was performed using the Mann–Whitney U test or the Student t-test. Categorical variables were presented as frequency (%) and compared between groups using Fisher’s exact test. A Kaplan–Meier time-to-event curve with a log-rank test was performed to compare the outcome by cardiac troponin quartile. The Cox proportional hazards regression model was used to assess the association between cardiac troponin levels and the risk of adverse cardiovascular events. The prognostic value of hs-cTnT and hs-cTnI on all-cause mortality and MACEs was determined as a hazard ratio (HR) and 95% confidence interval (CI). Statistical significance was defined as a P-value of less than 0.05. The statistical software package SPSS version 23 (IBM Corp., Armonk, NY, USA, https://www.ibm.com/products/spss-statistics) was used for statistical analysis and STATA version 16.2 (StataCorp, College Station, TX, USA, https://www.stata.com/order/new/edu/proplus/campus-proplus/) was used for graphic creation.

Ethics approval and consent to participate. The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients was approved by the ethics committee of the Faculty of Medicine, Chiang Mai University, approval number 182/2564. The investigations were carried out in accordance with the Declaration of Helsinki, including written informed consent of all participants.

Results

Study population and outcomes. A total of 198 asymptomatic patients with chronic hemodialysis were enrolled in this study. The median follow-up durations were 13.5 months, one patient lost to follow up and one received a kidney transplant. Table 1 shows baseline clinical characteristics and demographic data. The mean age of the patients was 62.4 ± 14.8 and 111 (56.1%) were male. Our studied population had a high prevalence of cardiovascular risk factors. There were 180 (90.9%) patients with hypertension, 89 (44.9%) patients with diabetes and 105 (53%) patients with dyslipidemia. The history of coronary artery disease, atrial fibrillation and cerebrovascular disease was evident in 26 (13.1%) patients, 23 (11.7%) patients, and 21 (10.6%) patients. The median dialysis vintage was 37.2 months. There were 187 (94.4%) patients receiving hemodialysis three times a week and the 11 (5.6%) receiving hemodialysis twice a week. The median hs-cTnI level was 61.1 (36.6–102.0) ng/L, with 196 (99%) individuals having hs-cTnI levels higher than the cutoff point (99th percentile upper reference limit of 14 ng/L). The median hs-cTnI level was 18.4 (9.5–36.6) ng/L, with hs-cTnI levels above the cutoff point (99th percentile upper reference limit of 26.2 ng/L) present in 68 (34.3%) participants. It has been demonstrated that the approved 99th-percentile of hs-cTnI (26.2 ng/L) may not be biologically equivalent of the 99th-percentile of hs-cTnI (14 ng/L). With this regard, we also used the cutoff point of 8.7 ng/L in female and 16 ng/L in male for the hs-cTnI. There were 127 (64.1%) patients who had level of hs-cTnI above this gender-specific cutoff point.
Among 198 patients with regular dialysis, the first occurrence of MACEs was reported in 30 patients (15.2%), including nonfatal myocardial infarction in 7 patients, heart failure hospitalization in 7 patients, and death from any cause in 16 patients. Among 30 patients who developed MACEs, 2 patients with nonfatal myocardial infarction and 2 patients with heart failure hospitalization subsequently died in separate events. As a result, a total of 20 (10.1%) patients died during follow-up, in which cardiovascular death occurred in 9 patients (4.5%).

The non-survivors were significantly older than the survivors (72.8 ± 11.8 vs. 61.3 ± 14.7 years, p < 0.001). Atrial fibrillation was non-significantly more prevalent in non-survivors (25.0% vs. 10.2%, P = 0.065), leading to the greater use of oral anticoagulants in non-survivors compared to survivors (30.0% vs. 7.0%, P = 0.005). The higher use of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) was also evident in non-survivor group (23.9% vs. 5.0%, P = 0.029). The presence of other co-morbidities did not differ between non-survivors and survivors. The significantly lower levels of hemoglobin and serum albumin were observed in non-survivors. Interestingly, non-survivors had significantly greater hs-cTnT levels compared to survivors.

| Characteristics | Total (N = 198) | Alive (N=178) | Dead (N = 20) | P-value |
|-----------------|----------------|---------------|---------------|---------|
| Mean age, years | 62.4 ± 14.8    | 61.3 ± 14.7   | 72.8 ± 11.8   | <0.001  |
| Gender          |                |               |               | 1.000   |
| Male            | 111 (56.1%)    | 100 (56.2%)   | 11 (55.0%)    |         |
| Female          | 87 (43.9%)     | 78 (43.9%)    | 9 (45.0%)     |         |
| Mean body mass index (kg/m²) | 23.1 ± 4.9    | 23.3 ± 5.2   | 21.4 ± 2.6   | 0.108   |
| Smoking status  |                |               |               | 0.695   |
| No smoking      | 144 (72.7%)    | 130 (73.0%)   | 14 (72.7%)    |         |
| Ex-smoker       | 41 (20.7%)     | 35 (19.7%)    | 6 (30.0%)     |         |
| Current smoker  | 4 (2%)         | 4 (2.2%)      | 0 (0%)        |         |
| Comorbidities   |                |               |               |         |
| Diabetes mellitus | 89 (44.9%)  | 79 (44.4%)   | 10 (50.0%)    | 0.681   |
| Dyslipidemia    | 105 (53.0%)    | 94 (52.8%)    | 11 (55.0%)    | 1.000   |
| Hypertension    | 180 (90.9%)    | 161 (90.9%)   | 19 (95.0%)    | 1.000   |
| Atrial fibrillation | 23 (11.7%) | 18 (10.2%)   | 5 (25.0%)     | 0.065   |
| Coronary artery disease | 26 (13.1%) | 23 (12.9%) | 3 (15.0%) | 0.733 |
| Cerebrovascular disease | 21 (10.6%) | 19 (10.7%) | 2 (10.0%) | 1.000 |
| Chronic obstructive pulmonary disease | 2 (1%) | 1 (0.6%) | 1 (5.0%) | 0.193 |
| Medication      |                |               |               |         |
| Antiplatelet    | 71 (35.9%)     | 64 (36.2%)    | 7 (35.0%)     | 1.000   |
| Beta-blockers   | 126 (63.6%)    | 113 (66.1%)   | 13 (65.0%)    | 1.000   |
| ACEi/ARB        | 51 (25.8%)     | 41 (23.9%)    | 10 (50.0%)    | 0.029   |
| Calcium channel blockers | 127 (64.1%) | 114 (66.7%) | 13 (65.0%) | 1.000 |
| Statins         | 112 (56.6%)    | 102 (59.6%)   | 10 (50.0%)    | 0.475   |
| Oral anticoagulant | 18 (9.1%) | 12 (7.0%) | 6 (30.0%) | 0.005 |
| Dialysis data   |                |               |               |         |
| Dialysis vintage (months), median (IQR) | 37.2 (22.4–60.3) | 37.5 (22.9–60.2) | 34.8 (21.9–61.2) | 0.773 |
| Dialysis frequency |            |               |               | 1.000   |
| 2 times per week | 11 (5.6%)     | 10 (5.6%)     | 1 (5.0%)      |         |
| 3 times per week | 187 (94.4%)   | 168 (94.4%)   | 19 (95.0%)    |         |
| Dialysis access |                |               |               | 0.619   |
| Arteriovenous fistula | 138 (69.7%) | 126 (70.8%) | 12 (63.2%) |         |
| Arteriovenous graft | 8 (4%)         | 7 (3.9%)    | 1 (5.3%)      |         |
| Perm catheter   | 50 (25.4%)     | 44 (24.7%)    | 6 (31.6%)     |         |
| Double lumen catheter | 1 (0.6%)   | 0 (0.0%)     | 1 (0.5%)      |         |
| Laboratory data |                |               |               |         |
| Serum sodium (mEq/L) | 136.7 ± 3.3 | 136.8 ± 3.3 | 135.9 ± 3.4 | 0.210 |
| Serum potassium (mEq/L) | 4.4 ± 0.6 | 4.5 ± 0.6 | 4.4 ± 0.6 | 0.526 |
| Hemoglobin (g/dL) | 10.4 ± 1.4 | 10.5 ± 1.4 | 9.6 ± 1.1 | 0.027 |
| Serum albumin (g/dL) | 4.0 ± 0.4 | 4.0 ± 0.4 | 3.5 ± 0.5 | <0.001 |
| hs-cTnI (ng/L), median (IQR) | 18.4 (9.5–36.6) | 17.2 (9.4–33.4) | 27.3 (13.3–43.4) | 0.105 |
| ≥ 26.2 ng/L | 68 (34.3%) | 58 (32.6%) | 10 (50%) | 0.139 |
| hs-cTnT (ng/L), median (IQR) | 61.1 (36.6–102.0) | 59.0 (36.0–95.8) | 111.4 (56.4–174.1) | 0.002 |
| ≥ 14 ng/L | 196 (99%) | 176 (98.9%) | 20 (100.0%) | 1.000 |

Table 1. Baseline characteristics of the population.
Costanzo et al. (2022) reported that hs-cTnI remained significantly associated with a greater risk of MACEs (HR 2.57; 95%CI 1.25–5.30, P = 0.010) compared to those in the lower quartile. Age was also another independent predictor of long-term mortality. A cut-off level of hs-cTnT ≥ 102 ng/L provided a sensitivity of 50%, a specificity of 78.1%, a positive predictive value of 20.4% and a negative predictive value of 93.0% to predict long-term mortality. Apart from the level of cTnI, serum albumin, hemoglobin, the use of ACEi/ARB and the use of oral anticoagulant were also significant between the survivors and non-survivors (111.4, IQR 56.4–174.1 vs. 59.0, IQR 36.0–95.8, P = 0.002), while hs-cTnI levels were not statistically different between two groups (p = 0.105) (Table 1).

### Prognostic values of hs-cTnT and hs-cTnI on long-term outcomes

We classified hs-cTnT and hs-cTnI into quartiles based on concentration. Regarding the hs-cTnT level, the first quartile, the second quartile, the third quartile and the fourth quartile had hs-cTnT levels < 36.5 ng/L, 36.5–61.0 ng/L, 61.1–101.9 ng/L, and ≥ 102.0 ng/L, respectively. With respect to the hs-cTnI level, the first quartile, the second quartile, the third quartile and the fourth quartile had hs-cTnI levels < 9.5 ng/L, 9.5–18.3 ng/L, 18.4–35.9 ng/L, ≥ 36.0 ng/L. To analyze the association between hs-cTn and clinical outcomes, hs-cTn data were compared between patients with values above the highest quartile of hs-cTnT (≥ 102 ng/L) and hs-cTnI (≥ 36 ng/L) and those with values below the highest quartile. The univariable and multivariable Cox regression analysis of hs-cTnT and hs-cTnI on long-term all-cause mortality were shown in Table 2. When compared to the lower quartile, patients in the highest quartile of hs-cTnT levels showed a higher risk of all-cause mortality (unadjusted HR 3.34; 95%CI 1.39–8.04, P = 0.005). The relationship between hs-cTn and all-cause mortality remained significant after adjusting for age and gender (adjusted HR 2.90; 95%CI 1.20–7.03, P = 0.018). On the other hand, hs-cTn levels above the highest quartile was not significantly associated with increased risk of all-cause mortality (unadjusted HR 2.10; 95%CI 0.86–5.13, P = 0.105 and adjusted HR 1.94; 95%CI 0.79–4.78, P = 0.147). To prevent the overfitting in the multivariate regression model, the number of potential variables adjusted in the Cox regression model for all-cause mortality was limited. As a result, only age and gender were adjusted in the main analysis. Nevertheless, we performed exploratory analysis to confirm the validity of multiple regression analysis. All variables with significant differences between the survivors and non-survivors were also adjusted in the Cox regression model. We demonstrated that the hs-cTnT (adjusted HR 2.64 [1.02–6.78]), but not hs-cTnI (adjusted HR 0.95 [0.31–2.85]), remained significantly associated with an increased risk of all-cause mortality after adjusting for age, atrial fibrillation, serum albumin, hemoglobin, the use of ACEI/ARB and the use of oral anticoagulant.

A cut-off level of hs-cTnT ≥ 102 ng/L provided a sensitivity of 50%, a specificity of 78.1%, a positive predictive value of 20.4% and a negative predictive value of 93.0% to predict long-term mortality. Apart from the level of hs-cTnT, age was also another independent predictor of long-term mortality.

According to the secondary outcome, patients with hs-cTnT level in the highest quartile was associated with a greater risk of MACEs (HR 2.57; 95%CI 1.25–5.30, P = 0.010) compared to those in the lower quartile. (Table 2) After adjusting for age, gender, and atrial fibrillation, the hs-cTnT remained significantly associated with the increased risk of MACEs (HR 2.27; 95%CI 1.09–4.71, P = 0.028). Similar to hs-cTnT level, hs-cTnI level demonstrated a significant relationship with the occurrence of MACEs (unadjusted HR 2.51; 95%CI 1.22–5.19, P = 0.012 and adjusted HR 2.25; 95%CI 1.07–5.35, P = 0.032). Figures 1 and 2 shows the Kaplan–Meier curves of the primary and secondary outcomes.

### Discussion

We demonstrated that nearly all of patients with chronic hemodialysis had an increased level of hs-cTnT and one-third of patients had an elevated level of hs-cTnI, similar to previous studies. Besides coronary artery disease, other factors enhancing the level of hs-cTnT in hemodialysis patients include left ventricular hypertrophy, impaired left ventricular systolic and diastolic function, volume overload, and repeatedly intradialytic hypotension. These conditions can lead to myocardial injury and myocardial necrosis. Consequently, the patients with these circumstances were more likely to develop cardiovascular adverse events. With this regard, the predictability of hs-cTnT on long-term cardiovascular events and mortality has been explored in several studies. As hs-cTnT differs from hs-cTnI in several aspects including the cellular distribution, biochemical profiles and analytical performances, it is possible that these two biomarkers may have different prognostic values on long-term outcome.

Our study showed that hs-cTnT and age were two independent predictors of long-term mortality in patients receiving regular hemodialysis. In contrast, hs-cTnI level was not significantly related with long-term mortality. Nevertheless, higher levels of hs-cTnT and hs-cTnI both were associated with an increased risk of long-term MACEs. Our findings were in line with previous studies. One used contemporary assay and the others used high-sensitivity assays in their studies. They showed that cTnT but not cTnI predicted long-term adverse outcomes.

### Table 2

| Variables                      | All-cause mortality | MACEs |
|-------------------------------|---------------------|-------|
|                               | HR (95%CI)          | P-value | HR (95%CI)          | P-value |
| hs-cTnT above highest quartile (≥ 102 ng/L) |                      |       |                     |         |
| Unadjusted OR                 | 3.34 (1.39–8.04)    | 0.007  | 2.57 (1.25–5.30)    | 0.010   |
| Adjusted OR                   | 2.90 (1.20–7.03)    | 0.018  | 2.27 (1.09–4.71)    | 0.028   |
| hs-cTnI above highest quartile (≥ 36 ng/L) |                      |       |                     |         |
| Unadjusted OR                 | 2.10 (0.86–5.13)    | 0.105  | 2.51 (1.22–5.19)    | 0.012   |
| Adjusted OR                   | 1.94 (0.79–4.78)    | 0.147  | 2.25 (1.07–3.35)    | 0.032   |

*Adjusted for age and gender. aAdjusted for age, gender, and atrial fibrillation.
The reason why hs-cTnT had a greater prognostic value on long-term mortality is unclear. Previous study has demonstrated a higher tissue concentration and free cytoplasmic concentrations in cTnT compared to cTnI. In addition, cTnT was observed in blood of patients with acute myocardial infarction as a mixture of complexed (cTnT-I-C) and free cTnT. On the contrary, cTnI was more hydrophobic and was detected dominantly in the binary complex (I-C) form, with lesser extents of the ternary (T-I-C) complex. Degradation of the complex led to more rapidly clearance of the protein11,21. With this regard, we proposed that hs-cTnT was possibly more sensitive to myocardial injury than hs-cTnI due to the higher concentration in tissue and free cytoplasm. Moreover, hs-cTnT may release more early with greater amount than hs-cTnI during myocardial injury. This disparity feasibly account for the much higher prevalence of elevated level of hs-cTnT in asymptomatic patients receiving regular hemodialysis, compared to hs-cTnI level. In addition, previous studies from our group and from Buiten et al. demonstrated similar findings that hs-cTnT was superior to hs-cTnI in predicting patients with history of coronary artery disease6,22. Therefore, patients with higher level of hs-cTnT may have higher prevalence of subclinical coronary artery disease which may contribute to the increased risk of long-term mortality. Nevertheless, some studies have reported the significant association of hs-cTnI and long-term adverse outcomes. Gaiki and colleagues determined the prognostic value of hs-cTnI in asymptomatic patients with hemodialysis. At a 2-year follow-up, they discovered that using a hs-cTnI was predictive of cardiac events23. The Vitros ES assay manufactured by Ortho Clinical Diagnostics was used in that study. Other studies from Artunc and colleagues have also shown that hs-cTnI was associated with long-term mortality. The troponin I Ultra assay on a Siemens ADVIA Centaur system was used in their studies18,24. On the other hands, our study along with others which demonstrated the lack of predictive power of hs-cTnI and adverse outcomes used hs-cTnI assay manufactured by Abbott Diagnostics3,8. With this regard, the diversity of predictive power of hs-cTnI among studies may be resulted from the use of different hs-cTnI assay.

Our study confirmed that elevated level of hs-cTnT can be used as a prognostic marker for long-term mortality in patients with regular hemodialysis. The optimal cutoff level of hs-cTnT for predicting the long-term mortality

Figure 1. Kaplan–Meier survival curve analysis for all-cause mortality in patients above or below the highest quartile of hs-cTnT (A) and hs-cTnI (B).

Figure 2. Kaplan–Meier survival curve analysis for MACEs in patients above or below the highest quartile of hs-cTnT (A) and hs-cTnI (B).
is unknown. We proposed the cutoff hs-cTnT level of 102 ng/L to predict long-term mortality with a sensitivity of 50%, a specificity of 78.1%, a positive predictive value of 20.4% and a negative predictive value of 93.0%.

Our study has a number of limitations. First, our study cohort was recruited from a single dialysis center and our sample size was relatively small. As a result, the generalizability of our findings is limited. Second, we did not include patients with chronic peritoneal dialysis. Therefore, our findings could not be applied in these populations. Third, since cardiac troponin levels were measured only once, it was difficult to show how changes in biomarkers affected the clinical outcome of patients. Fourth, other biomarkers that may have predicted the outcome such as C-reactive protein were not assessed in our studied population. Fifth, the constant effect of populations. Third, since cardiac troponin levels were measured only once, it was difficult to show how changes did not include patients with chronic peritoneal dialysis. Therefore, our findings could not be applied in these populations. Third, since cardiac troponin levels were measured only once, it was difficult to show how changes in biomarkers affected the clinical outcome of patients. Fourth, other biomarkers that may have predicted the outcome such as C-reactive protein were not assessed in our studied population.

Conclusions
We demonstrated that elevated hs-cTnT level, but not hs-cTnI, was associated with a higher risk of long-term mortality. Nevertheless, higher level of hs-cTnT and hs-cTnI both were associated with greater risk of long-term MACEs in patients with chronic hemodialysis.

Data availability
The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients does not cover data posting in public databases. However, data are available upon request should be sent to bwanwarang@yahoo.com and are subject to approval by the Faculty of Medicine, Chiang Mai University Ethics Committee.

Received: 20 April 2022; Accepted: 31 July 2022
Published online: 17 August 2022

References
1. Cheung, A. K. et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 65, 2380–2389. https://doi.org/10.1111/j.1523-1755.2004.00657.x (2004).
2. Wang, A. Y. & Lai, K. N. Use of cardiac biomarkers in end-stage renal disease. J. Am. Soc. Nephrol. 19, 1643–1652. https://doi.org/10.1681/asn.2008010012 (2008).
3. Hickman, P. E. et al. Multiple biomarkers including cardiac troponins T and I measured by high-sensitivity assays, as predictors of long-term mortality in patients with chronic renal failure who underwent dialysis. Am. J. Cardiol. 115, 1601–1606. https://doi.org/10.1016/j.amjcard.2015.02.066 (2015).
4. Lippi, G. et al. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch. Pathol. Lab. Med. 132, 72–76. https://doi.org/10.5858/ aphl.2008-132-72-inostau (2008).
5. Gremmelm, S., Fellay, B., Hemett, O. M., Magnin, J. L. & Descombes, E. Monthly measurement of high-sensitivity cardiac troponins T and creatinine kinase in asymptomatic chronic hemodialysis patients: A one-year prospective study. Hemodial. Int. https://doi.org/10.1111/idi.12985 (2021).
6. Wongcharoen, W., Chombandit, T., Phrommintikul, A. & Noppakun, K. Variability of high-sensitivity cardiac troponin T and I in asymptomatic patients receiving hemodialysis. Sci. Rep. 11, 17334. https://doi.org/10.1038/s41598-021-96638-0 (2021).
7. Kalaji, F. R. & Albitar, S. Predictive value of cardiac troponin T and I in hemodialysis patients. Saudi J. Kidney Dis. Transpl. 23, 939–945. https://doi.org/10.4103/sjkd.2012.100868 (2012).
8. Snaedal, S. et al. High-sensitivity troponins in dialysis patients: Variation and prognostic value. Clin. Kidney J. 14, 1789–1797. https://doi.org/10.1093/ckj/sfaa215 (2021).
9. Pianta, T. J. et al. Cardiac high-sensitivity troponin measurement: A layer of complexity in managing haemodialysis patients. Nephrology 17, 636–641. https://doi.org/10.1111/1440-1797.12625.x (2012).
10. Perrone, M. A. et al. Cardiac troponins: Are there any differences between T and I? J. Cardiovasc. Med. https://doi.org/10.2459/JCM.00000000000001155 (2021) (Publish Ahead of Print).
11. Wu, A. H. & Feng, Y. J. Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. Eur. Heart J. 19(Suppl N), N25–29 (1998).
12. Apple, F. S., Murakami, M. M., Pearce, L. A. & Herzig, C. A. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106, 2941–2945. https://doi.org/10.1161/01.cir.0000041254.30637.34 (2002).
13. Khan, I. A. et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: A two-year outcome analysis. J. Am. Coll. Cardiol. 38, 991–998. https://doi.org/10.1016/s0735-1097(01)01533-3 (2001).
14. Foley, R. N., Gilberson, D. T., Murray, T. & Collins, A. J. Long interdialytic interval and mortality among patients receiving hemodialysis. N. Engl. J. Med. 365, 1099–1107. https://doi.org/10.1056/NEJMoa1103313 (2011).
15. Wong, M. C. et al. Temporal distribution of arrhythmic events in chronic kidney disease: Highest incidence in the long interdialytic period. Heart Rhythm 12, 2047–2055. https://doi.org/10.1016/j.hrthm.2015.06.033 (2015).
16. Giannitsis, E. et al. Gender-specific reference values for high-sensitivity cardiac troponin T and I in well-phenotyped healthy individuals and validity of high-sensitivity assay designation. Clin. Biochem. 78, 18–24. https://doi.org/10.1016/j.clinbiochem.2019.11.013 (2020).
17. Wildi, K. et al. Misdiagnosis of myocardial infarction related to limitations of the current regulatory approach to define clinical decision values for cardiac troponin. Circulation 131, 2032–2040. https://doi.org/10.1161/CIRCULATIONAHA.114.014129 (2015).
18. Artunc, F. et al. Sensitive troponins—which suits better for hemodialysis patients? Associated factors and prediction of mortality. PLoS ONE 7, e47610. https://doi.org/10.1371/journal.pone.0047610 (2012).
19. Mbagaya, W., Luvai, A. & Lopez, B. Biological variation of cardiac troponin in stable haemodialysis patients. Ann. Clin. Biochem. 52, 562–568. https://doi.org/10.1177/0004563215588775 (2015).
20. Antlanger, M. et al. Fluid overload in hemodialysis patients: A cross-sectional study to determine its association with cardiac biomarkers and nutritional status. BMC Nephrol. 14, 266. https://doi.org/10.1186/1471-2369-14-266 (2013).
21. Freda, B. J., Tang, W. H., Van Lente, F., Peacock, W. F. & Francis, G. S. Cardiac troponins in renal insufficiency: Review and clinical implications. J. Am. Coll. Cardiol. 40, 2065–2071. https://doi.org/10.1016/S0735-1097(02)02608-6 (2002).
22. Buiten, M. S. et al. Serum cardiac troponin-I is superior to troponin-T as a marker for left ventricular dysfunction in clinically stable patients with end-stage renal disease. PLoS ONE 10, e0134245. https://doi.org/10.1371/journal.pone.0134245 (2015).
23. Gaiki, M. R., DeVita, M. V., Michelis, M. F., Panagopoulos, G. & Rosenstock, J. L. Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay. Int. Urol. Nephrol. 44, 1841–1845. https://doi.org/10.1007/s11255-012-0128-x (2012).
24. Artunc, E et al. Performance of a novel high sensitivity cardiac troponin I assay in asymptomatic hemodialysis patients—Evidence for sex-specific differences. Clin. Chem. Lab. Med. 57, 1261–1270. https://doi.org/10.1515/cclm-2018-1176 (2019).
25. Mavrakanas, T. A., Sniderman, A. D., Barre, P. E. & Alam, A. Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients. Nephrology 23, 69–74. https://doi.org/10.1111/nep.12945 (2018).

Acknowledgements
We would like to express our appreciation to all an effort and contribution the study support from Staffs in the Northern Dialysis Center and Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Author contributions
K.N. performed the statistical analyses, evaluated the results and drafted the paper. K.R. recruited patients and collected data. A.P. and N.O. contributed substantially to data preparation and quality assurance. W.W. designed study, participated in the conception and design of the study revised the paper for important academic content. All authors have read and approved the final manuscript.

Funding
This work was supported by the Faculty of Medicine Endowment Fund for medical research, Chiang Mai University, Thailand (167/2563). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to W.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022